These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31747968)

  • 21. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.
    Liu X; Li J; Liu Y; Ding J; Tong Z; Liu Y; Zhou Y; Liu Y
    Cell Immunol; 2016 Feb; 300():46-53. PubMed ID: 26702740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
    Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
    Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
    Corvigno S; Burks JK; Hu W; Zhong Y; Jennings NB; Fleming ND; Westin SN; Fellman B; Liu J; Sood AK
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3545-3555. PubMed ID: 34476576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.
    Zhang C; Cao K; Yang M; Wang Y; He M; Lu J; Huang Y; Zhang G; Liu H
    Oncoimmunology; 2023; 12(1):2261242. PubMed ID: 37791232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer.
    Kroeger DR; Milne K; Nelson BH
    Clin Cancer Res; 2016 Jun; 22(12):3005-15. PubMed ID: 26763251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytofluorometric assessment of calreticulin exposure on CD38
    Beltrán-Visiedo M; Serrano-Del Valle A; Jiménez-Aldúan N; Soler-Agesta R; Naval J; Galluzzi L; Marzo I
    Methods Cell Biol; 2024; 189():189-206. PubMed ID: 39393883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 33. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
    Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Siamakpour-Reihani S; Cobb LP; Jiang C; Zhang D; Previs RA; Owzar K; Nixon AB; Alvarez Secord A
    Gynecol Oncol; 2020 Mar; 156(3):662-668. PubMed ID: 31918995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
    Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
    Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
    Goc J; Germain C; Vo-Bourgais TK; Lupo A; Klein C; Knockaert S; de Chaisemartin L; Ouakrim H; Becht E; Alifano M; Validire P; Remark R; Hammond SA; Cremer I; Damotte D; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
    Cancer Res; 2014 Feb; 74(3):705-15. PubMed ID: 24366885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calreticulin-Multifunctional Chaperone in Immunogenic Cell Death: Potential Significance as a Prognostic Biomarker in Ovarian Cancer Patients.
    Kielbik M; Szulc-Kielbik I; Klink M
    Cells; 2021 Jan; 10(1):. PubMed ID: 33440842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.